1
|
Ceccarini MR, Fittipaldi S, Ciccacci C, Granese E, Centofanti F, Dalla Ragione L, Bertelli M, Beccari T, Botta A. Association Between DRD2 and DRD4 Polymorphisms and Eating Disorders in an Italian Population. Front Nutr 2022; 9:838177. [PMID: 35369087 PMCID: PMC8964431 DOI: 10.3389/fnut.2022.838177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 02/01/2022] [Indexed: 12/15/2022] Open
Abstract
Anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED) are the three most common eating disorders (EDs). Their etiopathogenesis is multifactorial where both the environmental and genetic factors contribute to the disease outcome and severity. Several polymorphisms in genes involved in the dopaminergic pathways seem to be relevant in the susceptibility to EDs, but their role has not been fully elucidated yet. In this study, we have analyzed the association between selected common polymorphisms in the DRD2 and DRD4 genes in a large cohort of Italian patients affected by AN (n = 332), BN (n = 122), and BED (n = 132) compared to healthy controls (CTRs) (n = 172). Allelic and genotypic frequencies have been also correlated with the main psychopathological and clinical comorbidities often observed in patients. Our results showed significant associations of the DRD2-rs6277 single nucleotide polymorphism (SNP) with AN and BN, of the DRD4-rs936461 SNP with BN and BED and of DRD4 120-bp tandem repeat (TR) polymorphism (SS plus LS genotypes) with BED susceptibility. Moreover, genotyping of DRD4 48-bp variable number TR (VNTR) identified the presence of ≥7R alleles as risk factors to develop each type of EDs. The study also showed that ED subjects with a history of drugs abuse were characterized by a significantly higher frequency of the DRD4 rs1800955 TT genotype and DRD4 120-bp TR short-allele. Our findings suggest that specific combinations of variants in the DRD2 and DRD4 genes are predisposing factors not only for EDs but also for some psychopathological features often coupled specifically to AN, BN, and BED. Further functional research studies are needed to better clarify the complex role of these proteins and to develop novel therapeutic compounds based on dopamine modulation.
Collapse
Affiliation(s)
- Maria Rachele Ceccarini
- Department of Pharmaceutical Science, University of Perugia, Perugia, Italy.,Consorzio Interuniversitario per le Biotecnologie (C.I.B), Trieste, Italy
| | - Simona Fittipaldi
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Cinzia Ciccacci
- UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy
| | - Erika Granese
- Department of Pharmaceutical Science, University of Perugia, Perugia, Italy
| | - Federica Centofanti
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - Laura Dalla Ragione
- Food Science and Human Nutrition Unit, University Campus Biomedico of Rome, Rome, Italy
| | | | - Tommaso Beccari
- Department of Pharmaceutical Science, University of Perugia, Perugia, Italy.,Consorzio Interuniversitario per le Biotecnologie (C.I.B), Trieste, Italy
| | - Annalisa Botta
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Fremont R, Manoochehri M, Armstrong NM, Mattay VS, Apud JA, Tierney MC, Devanand DP, Gazes Y, Habeck C, Wassermann EM, Grafman J, Huey ED. Tolcapone Treatment for Cognitive and Behavioral Symptoms in Behavioral Variant Frontotemporal Dementia: A Placebo-Controlled Crossover Study. J Alzheimers Dis 2021; 75:1391-1403. [PMID: 32444540 PMCID: PMC10131251 DOI: 10.3233/jad-191265] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND There are currently no disease-targeted treatments for cognitive or behavioral symptoms in patients with behavioral variant frontotemporal dementia (bvFTD). OBJECTIVE To determine the effect of tolcapone, a specific inhibitor of Catechol-O-Methyltransferase (COMT), in patients with bvFTD. METHODS In this randomized, double-blind, placebo-controlled, cross-over study at two study sites, we examined the effect of tolcapone on 28 adult outpatients with bvFTD. The primary outcome was reaction time on the N-back cognitive test. As an imaging outcome, we examined differences in the resting blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) signal intensity between subjects on placebo versus tolcapone performing the N-back test. Secondary outcomes included measures of cognitive performance and behavioral disturbance using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Neuropsychiatric Inventory-Questionnaire (NPI-Q), and Clinical Global Impressions scale (CGI). RESULTS Tolcapone was well tolerated and no patients dropped out. The most frequent treatment-related adverse event during tolcapone treatment was elevated liver enzymes (21%). There were no significant differences between tolcapone treatment and placebo in the primary or imaging outcomes. However, there were significant differences between RBANS total scores (p < 0.01), NPI-Q total scores (p = 0.04), and CGI total scores (p = 0.035) between treatment conditions which were driven by differences between baseline and tolcapone conditions. Further, there was a trend toward significance between tolcapone and placebo on the CGI (p = 0.078). CONCLUSIONS Further study of COMT inhibition and related approaches with longer duration of treatment and larger sample sizes in frontotemporal lobar degeneration-spectrum disorders may be warranted.
Collapse
Affiliation(s)
- Rachel Fremont
- Department of Psychiatry, Columbia University, New York, NY, USA
| | - Masood Manoochehri
- Taub Institute, Columbia University, New York, NY, USA.,Department of Neurology, Columbia University, New York, NY, USA
| | | | - Venkata S Mattay
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA.,Departments of Neurology and Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Jose A Apud
- Section on Integrative Neuroimaging, Clinical & Translational Neuroscience Branch, Intramural Research Program, NIMH/NIH, Bethesda, MD, USA
| | - Mary C Tierney
- Behavioral Neurology Unit, Intramural Research Program, NINDS/NIH, Bethesda, MD, USA
| | - D P Devanand
- Department of Psychiatry, Columbia University, New York, NY, USA
| | - Yunglin Gazes
- Department of Neurology, Columbia University, New York, NY, USA
| | | | - Eric M Wassermann
- Behavioral Neurology Unit, Intramural Research Program, NINDS/NIH, Bethesda, MD, USA
| | - Jordan Grafman
- Department of Physical Medicine and Rehabilitation, Cognitive Neuroscience Laboratory, Brain Injury Research, Shirley Ryan AbilityLab, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.,Departments of Neurology, Psychiatry, and Cognitive Neurology & Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA
| | - Edward D Huey
- Department of Psychiatry, Columbia University, New York, NY, USA.,Taub Institute, Columbia University, New York, NY, USA.,Department of Neurology, Columbia University, New York, NY, USA
| |
Collapse
|
3
|
Huey ED, Fremont R, Manoochehri M, Gazes Y, Lee S, Cosentino S, Tierney M, Wassermann EM, Momeni P, Grafman J. Effect of Functional BDNF and COMT Polymorphisms on Symptoms and Regional Brain Volume in Frontotemporal Dementia and Corticobasal Syndrome. J Neuropsychiatry Clin Neurosci 2020; 32:362-369. [PMID: 32397876 PMCID: PMC7606216 DOI: 10.1176/appi.neuropsych.19100211] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The authors examined the effects of two common functional polymorphisms-brain-derived neurotrophic factor (BDNF) Val66Met and catechol-O-methyltransferase (COMT) Val158Met-on cognitive, neuropsychiatric, and motor symptoms and MRI findings in persons with frontotemporal lobar degeneration (FTLD) syndromes. METHODS The BDNF Val66Met and COMT Val158Met polymorphisms were genotyped in 174 participants with FTLD syndromes, including behavioral variant frontotemporal dementia, primary progressive aphasia, and corticobasal syndrome. Gray matter volumes and scores on the Delis-Kaplan Executive Function System, Mattis Dementia Rating Scale, Wechsler Memory Scale, and Neuropsychiatric Inventory were compared between allele groups. RESULTS The BDNF Met allele at position 66 was associated with a decrease in depressive symptoms (F=9.50, df=1, 136, p=0.002). The COMT Val allele at position 158 was associated with impairment of executive function (F=6.14, df=1, 76, p=0.015) and decreased bilateral volume of the head of the caudate in patients with FTLD (uncorrected voxel-level threshold of p<0.001). Neither polymorphism had a significant effect on motor function. CONCLUSIONS These findings suggest that common functional polymorphisms likely contribute to the phenotypic variability seen in patients with FTLD syndromes. This is the first study to implicate BDNF polymorphisms in depressive symptoms in FTLD. These results also support an association between COMT polymorphisms and degeneration patterns and cognition in FTLD.
Collapse
Affiliation(s)
- Edward D. Huey
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, 630 W 168th St, P&S Box 16, New York, NY, 10032
- Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY
- Department of Neurology, Columbia University College of Physicians and Surgeons, College of Physicians and Surgeons, Columbia University, New York, NY
- Cognitive Neuroscience Section, NIH/NINDS, Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
| | - Rachel Fremont
- Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY
| | - Masood Manoochehri
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, 630 W 168th St, P&S Box 16, New York, NY, 10032
- Department of Neurology, Columbia University College of Physicians and Surgeons, College of Physicians and Surgeons, Columbia University, New York, NY
| | - Yunglin Gazes
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, 630 W 168th St, P&S Box 16, New York, NY, 10032
- Department of Neurology, Columbia University College of Physicians and Surgeons, College of Physicians and Surgeons, Columbia University, New York, NY
| | - Seonjoo Lee
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY
| | - Stephanie Cosentino
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, 630 W 168th St, P&S Box 16, New York, NY, 10032
- Department of Neurology, Columbia University College of Physicians and Surgeons, College of Physicians and Surgeons, Columbia University, New York, NY
| | - Michael Tierney
- Cognitive Neuroscience Section, NIH/NINDS, Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
| | - Eric M. Wassermann
- Cognitive Neuroscience Section, NIH/NINDS, Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
| | | | - Jordan Grafman
- Cognitive Neuroscience Section, NIH/NINDS, Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
- Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago, IL
| |
Collapse
|